Can the pharmaceutical industry reduce attrition rates?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Part of the attrition may be due to low animal-to-human translational success rates; the so-called “translational failure” [3].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [3]
In the citing paper
“Even so, late-stage attritions are still frequent [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Inhibition of the hERG channel can be an indicator of the APD prolongation and cardiotoxicity in early stages of drug development [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Less than 20 years ago, developing a drug took ~12 years, cost under a billion dollars, and the biggest challenges were failures due to efficacy or toxicity-induced attrition2.”
From Exploiting machine learning for end-to-end drug discovery and development (2019) · cites this paper as [2]
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265 · cited 1×
“In 2001, the costs of discovering and developing a drug were of the order of US d804 millio”
BackgroundRoberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“We have, in a similar manner, provided very strong evidence that inhibition of β-secretase inhibits the production of amyloid-β in knockout mic”
ResultGowen, M., Lazner, F., Dodds, R., Kapadia, R., Feild, J., Tavaria, M., Bertoncello, I., Drake, F., Zavarselk, S., Tellis, I., et al. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1654 · Cited by 490
Self-citationMa, P., & Zemmel, R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd884 · Cited by 174
Booth, B. L., Glassman, R. H., & Ma, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1158 · Cited by 84
An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling
Lazner, F., Gowen, M., & Kola, I. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01563-4 · Cited by 18 · cited 1×
“and that cathepsin K is involved in bone resorption (further compelling proof of mechanism is provided by humans with pycnodysostosi”
BackgroundSelf-citation2003 approvals: a year of innovation and upward trends
Frantz, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1327 · Cited by 15
Research works printed but not linked: 4
- Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5–10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).
- Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19–20 June (2002).
- Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03–202 R (CMR International Surrey, UK, 2003).
- Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).
Cited by
Items 101–200 of 1,025
Targeted Therapies for Hepatocellular Carcinoma
Villanueva, A., & Llovet, J. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.006 · Cited by 449
Drug–target residence time: critical information for lead optimization
Lu, H., & Tonge, P. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.176 · Cited by 432
“Introduction A primary source of attrition during drug discovery stems from poor in vivo efficacy [1].”
Sung, J. H., & Shuler, M. L. (2009) · Lab on a Chip · doi:10.1039/b901377f · Cited by 431
Target deconvolution strategies in drug discovery
Terstappen, G. C., Schlüpen, C., Raggiaschi, R., & Gaviraghi, G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2410 · Cited by 429
Vatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
“220 In this context, in silico ADME ‐”
Molecular mechanisms for tumour resistance to chemotherapy
Pan, S., Li, Z., He, Z., Qiu, J., & Zhou, S. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12581 · Cited by 401
Whitebread, S., Hamon, J., Bojanic, D., & Urban, L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03632-9 · Cited by 404
Traditional medicine-inspired approaches to drug discovery: can Ayurveda show the way forward?
Patwardhan, B., & Mashelkar, R. A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.009 · Cited by 390
Huang, R., Southall, N., Wang, Y., Yasgar, A., Shinn, P., Jadhav, A., Nguyen, D.-T., & Austin, C. P. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001862 · Cited by 401
“Drug toxicity is a major reason that new drug development programs fail (72), and approved drugs are regularly removed from the market because of adverse e ects; frequently, the mechanism by which the toxicity occurs is not known.”
BackgroundLee, J., Vali, Y., Boursier, J., Spijker, R., Anstee, Q. M., Bossuyt, P. M., & Zafarmand, M. H. (2021) · Liver International · doi:10.1111/liv.14669 · Cited by 378
Lead‐Oriented Synthesis: A New Opportunity for Synthetic Chemistry
Nadin, A., Hattotuwagama, C., & Churcher, I. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201105840 · Cited by 390
Mechanisms of Drug Toxicity and Relevance to Pharmaceutical Development
Guengerich, F. P. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-rv-062 · Cited by 387
New approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
Covalent inhibitors: a rational approach to drug discovery
Sutanto, F., Konstantinidou, M., & Dömling, A. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00154f · Cited by 389
In vitro models for the prediction of in vivo performance of oral dosage forms
Kostewicz, E. S., Abrahamsson, B., Brewster, M., Brouwers, J., Butler, J., Carlert, S., Dickinson, P. A., Dressman, J., Holm, R., Klein, S., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.08.024 · Cited by 373
“Since lack of efficacy and safety concerns are the largest contributors to attrition (J Arrowsmith, 2011a, b; Kola and Landis, 2004), this scientific and predictive approach is especially important when understanding therapeutic drug targets, mechanisms causing toxicological effects and drugdrug…”
BackgroundRuggeri, B. A., Camp, F., & Miknyoczki, S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.020 · Cited by 365
“For example, earlier assessments by Kola and Landis [23] reported only a 1 in 20 success rate (95% attrition) for oncology drugs, while more recent”
ResultAdvances in De Novo Drug Design: From Conventional to Machine Learning Methods
Mouchlis, V. D., Afantitis, A., Serra, A., Fratello, M., Papadiamantis, A. G., Aidinis, V., Lynch, I., Greco, D., & Melagraki, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041676 · Cited by 353
“The development of a chemical entity and its testing, evaluation, and authorization to become a marketed drug is a laborious and expensive process that is prone to failure [1].”
BackgroundKramer, J. A., Sagartz, J. E., & Morris, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2378 · Cited by 372
The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment
Pedrique, B., Strub-Wourgaft, N., Some, C., Olliaro, P., Trouiller, P., Ford, N., Pécoul, B., & Bradol, J.-H. (2013) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70078-0 · Cited by 352
Natural products for human health: an historical overview of the drug discovery approaches
Bernardini, S., Tiezzi, A., Laghezza Masci, V., & Ovidi, E. (2018) · Natural Product Research · doi:10.1080/14786419.2017.1356838 · Cited by 355
“The reasons of such declining trend are very complex (Kola and Landis 2004) and the most important evidence is that the chemical diversity of the compounds contained in the synthetic libraries is often nearly or completely absent (Bauer et al.”
BackgroundMolecular obesity, potency and other addictions in drug discovery
Hann, M. M. (2011) · MedChemComm · doi:10.1039/c1md00017a · Cited by 363
“, attrition) in 1991 to those in 2000 showed a shift to an increase in failure attributed to toxicological reasons [2].”
BackgroundHow can we improve the pre-clinical development of drugs for stroke?
Sena, E., van der Worp, H. B., Howells, D., & Macleod, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.06.009 · Cited by 365
Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01255.x · Cited by 363
“Such attrition can occur during preclinical or clinical development and post-approval stage, resulting in withdrawal of marketed drugs accounting for approximately one-third of all drug discontinuation (Figure 1; Kennedy, 1997; Lasser et al., 2002; Kola and Landis, 2004; Shah, 2006; Redfern et al., 2010).”
BackgroundA systematic interaction map of validated kinase inhibitors with Ser/Thr kinases
Fedorov, O., Marsden, B., Pogacic, V., Rellos, P., Müller, S., Bullock, A. N., Schwaller, J., Sundström, M., & Knapp, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708800104 · Cited by 359
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“Developing novel pharmaceutical agents is a costly enter- prise, and many candidate drugs fall by the wayside during the development process (see e.g. Dobson et al. 2009b; Kola and Landis 2004; Leeson and Springthorpe 2007).”
BackgroundMethodChemical space as a source for new drugs
Reymond, J.-L., van Deursen, R., Blum, L. C., & Ruddigkeit, L. (2010) · MedChemComm · doi:10.1039/c0md00020e · Cited by 347
Computational/in silico methods in drug target and lead prediction
Agamah, F. E., Mazandu, G. K., Hassan, R., Bope, C. D., Thomford, N. E., Ghansah, A., & Chimusa, E. R. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz103 · Cited by 328
“Thisresult is significantlyincreasing attrition rate [5].”
Skin-on-a-chip model simulating inflammation, edema and drug-based treatment
Wufuer, M., Lee, G., Hur, W., Jeon, B., Kim, B. J., Choi, T. H., & Lee, S. (2016) · Scientific Reports · doi:10.1038/srep37471 · Cited by 356
Cellular imaging in drug discovery
Lang, P., Yeow, K., Nichols, A., & Scheer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2008 · Cited by 351
Estimation of ADME Properties with Substructure Pattern Recognition
Shen, J., Cheng, F., Xu, Y., Li, W., & Tang, Y. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100104j · Cited by 349
Why is cancer drug discovery so difficult?
Kamb, A., Wee, S., & Lengauer, C. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2155 · Cited by 339
Kadurin, A., Aliper, A., Kazennov, A., Mamoshina, P., Vanhaelen, Q., Khrabrov, K., & Zhavoronkov, A. (2017) · Oncotarget · doi:10.18632/oncotarget.14073 · Cited by 350
“%) likelihood of approval (LOA) after Phase I [1, 3, 4].”
BackgroundAldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery
Pryde, D. C., Dalvie, D., Hu, Q., Jones, P., Obach, R. S., & Tran, T.-D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100888d · Cited by 345
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
Pangalos, M. N., Schechter, L. E., & Hurko, O. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2094 · Cited by 336
In silico methods for drug repurposing and pharmacology
Hodos, R. A., Kidd, B. A., Shameer, K., Readhead, B. P., & Dudley, J. T. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1337 · Cited by 326
Alex, A., Millan, D. S., Perez, M., Wakenhut, F., & Whitlock, G. A. (2011) · MedChemComm · doi:10.1039/c1md00093d · Cited by 329
Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology
Ewart, L., Apostolou, A., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K.-J., Joshipura, S. R., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00209-1 · Cited by 337
What's wrong with our cancer models?
Kamb, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1635 · Cited by 335
The Role of Body-on-a-Chip Devices in Drug and Toxicity Studies
Esch, M. B., King, T. L., & Shuler, M. L. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124629 · Cited by 328
“Saiyong Zhu, Wanguo Wei, and Sheng Ding 73 In Vitro Models of Traumatic Brain Injury Barclay Morrison III, Benjamin S. Elkin, Jean-Pierre Dollé, and Martin L. Yarmush 91”
BackgroundInfluentialIrreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Barf, T., & Kaptein, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003203 · Cited by 331
Henderson, V. C., Kimmelman, J., Fergusson, D., Grimshaw, J. M., & Hackam, D. G. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001489 · Cited by 302
“By recent estimates, 11% of agents entering clinical testing are ultimately licensed [1], and only 5% of ‘‘high impact’’ basic science discoveries claiming clinical relevance are successfully translated into approved agents within a decade [2].”
BackgroundSleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329
“candidates progress to the next phase in clinical trials (5), and the approval rate of cancer drugs entering phase I trials has previously been as low as 5 % (6).”
BackgroundRemoving Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., & Steckler, T. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.173 · Cited by 328
“Considering the long timelines for bringing a drug to market (12 years 10 months for all drugs registered in 2002; Kola and Landis, 2004; http://www.fda.gov/cder/regulatory/applications/), considerable pressure exists to achieve preclinical PoC as rapidly as possible so that clinical trials may be…”
InfluentialBender, A., Scheiber, J., Glick, M., Davies, J. W., Azzaoui, K., Hamon, J., Urban, L., Whitebread, S., & Jenkins, J. L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700026 · Cited by 327
Kummar, S., Kinders, R., Gutierrez, M. E., Rubinstein, L., Parchment, R. E., Phillips, L. R., Ji, J., Monks, A., Low, J. A., Chen, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7681 · Cited by 326
“The low success rate of new molecular entities and the development of molecularly targeted agents for the treatment of cancer have necessitated reevaluation of the standard anticancer drug development paradigm.(1) Recognizing that lack of predictive preclinical models, prolonged timelines, and high costs have hampered…”
Background3D bioprinting for drug discovery and development in pharmaceutics
Peng, W., Datta, P., Ayan, B., Ozbolat, V., Sosnoski, D., & Ozbolat, I. T. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.05.025 · Cited by 313
“due to the unpredictable nature of the drug targets and to the lack of models with the capability of reliably predicting human physiology [136].”
BackgroundChanging R&D models in research-based pharmaceutical companies
Schuhmacher, A., Gassmann, O., & Hinder, M. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0838-4 · Cited by 286
“• lack of reliability of published data [14], • biopharmaceutical issues including suboptimal PK [4], • poorly predictive preclinical models in discovery research and preclinical testing [15], • the concept of target-based drug discovery with the related advanced complexity of target selection, a competition for propr…”
BackgroundAdaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group
Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., & Pinheiro, J. (2006) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400600614742 · Cited by 323
“Ineffective therapies could be discontinued earlier with more confidence, and the late stage attrition rate, currently estimated at 45% in Phase III (Kola and Landis, 2004), could be reduced by facilitating the right dose or doses being taken forward in confirmatory trials.”
BackgroundInfluentialZhu, T., Cao, S., Su, P.-C., Patel, R., Shah, D., Chokshi, H. B., Szukala, R., Johnson, M. E., & Hevener, K. E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301916b · Cited by 313
Demystifying Brain Penetration in Central Nervous System Drug Discovery: Miniperspective
Di, L., Rong, H., & Feng, B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301297f · Cited by 304
Network Pharmacology: A New Approach for Chinese Herbal Medicine Research
Zhang, G.-B., Li, Q.-Y., Chen, Q.-L., & Su, S.-B. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/621423 · Cited by 300
The future of molecular dynamics simulations in drug discovery
Borhani, D. W., & Shaw, D. E. (2012) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9517-y · Cited by 313
“Poor pharmacokinetic properties, once a major issue, now account for just * 10% of clinical failures, mostly in Phase I [15], a gratifying result of the increased attention paid to these critical properties during lead optimization.”
BackgroundAnimal to human translation: a systematic scoping review of reported concordance rates
Leenaars, C. H. C., Kouwenaar, C., Stafleu, F. R., Bleich, A., Ritskes-Hoitinga, M., De Vries, R. B. M., & Meijboom, F. L. B. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1976-2 · Cited by 314
Fan, J., & de Lannoy, I. A. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.007 · Cited by 309
Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience
Mertens, J., Marchetto, M. C., Bardy, C., & Gage, F. H. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.46 · Cited by 307
A practical view of ‘druggability’
Keller, T. H., Pichota, A., & Yin, Z. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.014 · Cited by 295
“Introduction During the 1990s, the pharmaceutical industry noticed that too many compounds were terminated in clinical development because of unsatisfactory pharmacokinetics (PK) [1 ].”
BackgroundSystems biology, metabolic modelling and metabolomics in drug discovery and development
Kell, D. B. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.004 · Cited by 297
Cooper, T. W. J., Campbell, I. B., & Macdonald, S. J. F. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201002238 · Cited by 299
Prediction of ADMET Properties
Norinder, U., & Bergström, C. A. S. (2006) · ChemMedChem · doi:10.1002/cmdc.200600155 · Cited by 285
Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy
Dallmann, R., Okyar, A., & Lévi, F. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.004 · Cited by 293
“However, unanticipated or overwhelming adverse effects represent severe limitations, resulting in both drug attrition [33,34] and postmarketing withdrawal of several otherwise effective medications [35,36].”
BackgroundThe Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.008 · Cited by 295
“Essentially all oncology therapeutic candidates tested in humans have preclinical activity yet over 90% of these agents fail during clinical development (Kola and Landis, 2004; Ledford, 2011; Mak et al., 2014).”
A Guide to In Silico Drug Design
Chang, Y., Hawkins, B. A., Du, J. J., Groundwater, P. W., Hibbs, D. E., & Lai, F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010049 · Cited by 250
“Unfavourable pharmacokinetic and toxicity profile of a drug candidate is one of the hurdles that often leads to failure in the clinical trials [20].”
BackgroundZebrafish embryos as models for embryotoxic and teratological effects of chemicals
Yang, L., Ho, N. Y., Alshut, R., Legradi, J., Weiss, C., Reischl, M., Mikut, R., Liebel, U., Müller, F., & Strähle, U. (2009) · Reproductive Toxicology · doi:10.1016/j.reprotox.2009.04.013 · Cited by 283
Advanced Cell Culture Techniques for Cancer Drug Discovery
Lovitt, C., Shelper, T., & Avery, V. (2014) · Biology · doi:10.3390/biology3020345 · Cited by 282
“Through these drug development practices, the attrition rates of drug candidates for cancer are significant, being approximately 95% [3].”
Baranczewski, P., Stańczak, A., Sundberg, K., Svensson, R., Wallin, A., Jansson, J., Garberg, P., & Postlind, H. (2006) · PubMed · Cited by 344
Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P. J., Whitmore, A. V., Zimmer, S., Young, M. P., Jenkins, J. L., Glick, M., Glen, R. C., et al. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.05.011 · Cited by 287
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research
DANHOF, M., DELANGE, E., DELLAPASQUA, O., PLOEGER, B., & VOSKUYL, R. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.01.007 · Cited by 287
Drug Repurposing for Rare Diseases
Roessler, H. I., Knoers, N. V. A. M., van Haelst, M. M., & van Haaften, G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.01.003 · Cited by 269
A network view of disease and compound screening
Schadt, E. E., Friend, S. H., & Shaywitz, D. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2826 · Cited by 291
Mendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.2 · Cited by 133
Pluripotent stem cell-derived hepatocyte-like cells
Schwartz, R. E., Fleming, H. E., Khetani, S. R., & Bhatia, S. N. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.01.003 · Cited by 282
Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
Zamboni, W. C., Torchilin, V., Patri, A. K., Hrkach, J., Stern, S., Lee, R., Nel, A., Panaro, N. J., & Grodzinski, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2938 · Cited by 275
The State of Innovation in Drug Development
Kola, I. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100479 · Cited by 276
Self-citationPollastri, M. P. (2010) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0912s49 · Cited by 239
The necessity of animal models in pain research
Mogil, J. S., Davis, K. D., & Derbyshire, S. W. (2010) · Pain · doi:10.1016/j.pain.2010.07.015 · Cited by 259
“1) to drug registration for pain-related pharmaceuticals compared to 11% for all drug categories [29], although it should be noted that”
BackgroundStimulated Raman scattering microscopy: an emerging tool for drug discovery
Tipping, W. J., Lee, M., Serrels, A., Brunton, V. G., & Hulme, A. N. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00693g · Cited by 266
Mendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.1 · Cited by 266
Conn, P. J., Lindsley, C. W., Meiler, J., & Niswender, C. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4308 · Cited by 260
The multicellular tumor spheroid model for high-throughput cancer drug discovery
LaBarbera, D. V., Reid, B. G., & Yoo, B. H. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.708334 · Cited by 255
“Cancer drug discovery is a highly complex and multidisciplinary process, which currently has a low success rate (5%) and high cost (~$800 million) associated with translating an investigational new drug to clinical approval [11].”
BackgroundAntiviral drug discovery: preparing for the next pandemic
Adamson, C. S., Chibale, K., Goss, R. J. M., Jaspars, M., Newman, D. J., & Dorrington, R. A. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01118e · Cited by 250
Mitigating Heterocycle Metabolism in Drug Discovery
Jean, D. J. S., & Fotsch, C. H. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300343m · Cited by 263
Drug repositioning for personalized medicine
Li, Y. Y., & Jones, S. J. (2012) · Genome Medicine · doi:10.1186/gm326 · Cited by 248
“The importance of drug repositioning in the era of genomic medicine e perceived inefficiency of pharmaceutical drug development has been widely discussed [1-5].”
BackgroundResultInfluentialDevelopment of HPMA copolymer–anticancer conjugates: Clinical experience and lessons learnt
Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.007 · Cited by 252
Takebe, T., Imai, R., & Ono, S. (2018) · Clinical and Translational Science · doi:10.1111/cts.12577 · Cited by 238
Fast Dissolving Curcumin Cocrystals
Sanphui, P., Goud, N. R., Khandavilli, U. B. R., & Nangia, A. (2011) · Crystal Growth & Design · doi:10.1021/cg200704s · Cited by 253
Current industrial practices of assessing permeability and P-glycoprotein interaction
Balimane, P. V., Han, Y.-H., & Chong, S. (2006) · The AAPS Journal · doi:10.1208/aapsj080101 · Cited by 258
Bang, S., Lee, S.-R., Ko, J., Son, K., Tahk, D., Ahn, J., Im, C., & Jeon, N. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-07416-0 · Cited by 246
Physical Properties of Nanoparticles That Result in Improved Cancer Targeting
Zein, R., Sharrouf, W., & Selting, K. (2020) · Journal of Oncology · doi:10.1155/2020/5194780 · Cited by 243
“A century has passed since this discovery and yet only 1 in 10 drugs gain Food and Drug Administration (FDA) approval, primarily due to the lack of efficacy in later stage clinical trials [2].”
BackgroundRisk in vaccine research and development quantified
Pronker, E. S., Weenen, T. C., Commandeur, H., Claassen, E. H. J. H. M., & Osterhaus, A. D. M. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057755 · Cited by 253
“Moreover, this paper does not address orphan vaccines targeting unmet medical needs, whether projects are in-licensed or self-originated and firm size and experience [14,30,31].”
BackgroundHuang, R., Xia, M., Nguyen, D.-T., Zhao, T., Sakamuru, S., Zhao, J., Shahane, S. A., Rossoshek, A., & Simeonov, A. (2016) · Frontiers in Environmental Science · doi:10.3389/fenvs.2015.00085 · Cited by 227
“In fact, more than 30% of promising pharmaceuticals have failed in human clinical trials because they were found to be toxic despite promising pre-clinical studies in animal models (Kola and Landis, 2004).”
BackgroundThe influence of the gut microbiota on the bioavailability of oral drugs
Zhang, X., Han, Y., Huang, W., Jin, M., & Gao, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.013 · Cited by 242
van der Graaf, P. H., & Benson, N. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0467-9 · Cited by 248
“assertion that arguably the most significant challenge facing the pharmaceutical industry is compound attrition, resulting from the failure of preclinical efficacy and safety model data to translate into human proof-of-mechanism/concept studies (9,10).”
BackgroundArtificial Intelligence Approaches for Rational Drug Design and Discovery
Duch, W., Swaminathan, K., & Meller, J. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207780765954 · Cited by 243
Human Experimental Pain Models for Assessing the Therapeutic Efficacy of Analgesic Drugs
Olesen, A. E., Andresen, T., Staahl, C., & Drewes, A. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005447 · Cited by 239
“There could be several reasons for this lack of success in drug development, but one of the explanations could be that the preclinical pain models do not properly predict the clinical efficacy in humans (Kola and Landis, 2004; Chizh et al., 2009).”
BackgroundThe relevance and potential roles of microphysiological systems in biology and medicine
Wikswo, J. P. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214542068 · Cited by 248
“Nowhere would such predictions be more important than in support of the development of new drugs, in particular the anticipation of the efficacy, toxicity, and safety of a drug in humans.(13,14) Although there is a growing suite of techniques, primarily through optogenetics,(15,16) that enable interrogation of intact…”
BackgroundImproving the odds of drug development success through human genomics: modelling study
Hingorani, A. D., Kuan, V., Finan, C., Kruger, F. A., Gaulton, A., Chopade, S., Sofat, R., MacAllister, R. J., Overington, J. P., Hemingway, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54849-w · Cited by 247
MONN: A Multi-objective Neural Network for Predicting Compound-Protein Interactions and Affinities
Li, S., Wan, F., Shu, H., Jiang, T., Zhao, D., & Zeng, J. (2020) · Cell Systems · doi:10.1016/j.cels.2020.03.002 · Cited by 248
Meanwell, N. A. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00043 · Cited by 239
Akhtar, A., Andleeb, A., Waris, T. S., Bazzar, M., Moradi, A.-R., Awan, N. R., & Yar, M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.021 · Cited by 240
Hopkins, M. M., Martin, P. A., Nightingale, P., Kraft, A., & Mahdi, S. (2007) · Research Policy · doi:10.1016/j.respol.2007.02.013 · Cited by 234
Metadata
- Authors
- Kola, I., & Landis, J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kola, Ismail
- ORCID
- Landis, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-08
- Volume
- 3
- Issue
- 8
- Pages
- 711-716
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1895993106
- Cited by
- 4,167
- References
- 7
- Citations by year
- 2026: 121 · 2025: 129 · 2024: 126 · 2023: 159 · 2022: 165 · 2021: 188 · 2020: 179 · 2019: 203 · 2018: 183 · 2017: 194 · 2016: 256 · 2015: 294 · 2014: 279 · 2013: 307 · 2012: 300
- FWCI
- 199.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Keywords
- pharmaceutical industry, attrition rates, R&D productivity, drug development costs, health care cost containment, drug costs, R&D investment
- MeSH terms
- Clinical Trials as Topic, Drug Industry, Humans, Pharmacokinetics, Drug Design, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.